1527-17-9

Basic information

• Product Name: 2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID
• Synonyms: (o-(phenylthio)phenyl)-aceticaci;2-(phenylthio)benzeneaceticacid;[2-(PHENYLSULFANYL)PHENYL]ACETIC ACID;2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID;o-(Phenylthio)phenylacetic acid;2-[2-(phenylsulfanyl)phenyl]acetic acid
• CAS NO: 1527-17-9
• Molecular Formula: C₁₄H₁₂O₂S
• Molecular Weight: 244.31
• Mol File: 1527-17-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 116℃
• Boiling Point: 396.283 °C at 760 mmHg
• Flash Point: 193.465 °C
• Appearance: /
• Density: 1.276 g/cm³
• Vapor Pressure: 5.43E-07mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: 2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID(1527-17-9)
• EPA Substance Registry System: 2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID(1527-17-9)

Safety Data

• Hazard Codes: Xi
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 1527-17-9(Hazardous Substances Data)

Usage

General Description

The substance, "2-[2-(Phenylthio)phenyl]acetic acid," is an organic compound with a diverse molecular structure featuring an acetic acid group, a phenylthio group, and two phenyl rings. The presence of the phenyl rings indicates aromaticity, hence the compound may exhibit the unique properties of aromatic compounds, such as stability and strong intermolecular forces. As an acid, it has the ability to donate a proton (H+) in a reaction. Additionally, the phenylthio group, composed of a sulfur atom linking a phenyl ring and a hydrogen atom, could contribute to possible bioactivity or instability based on the known reactivity of sulfur compounds. However, the exact behavior, reactivity, and potential uses of this compound depend on more specific factors, such as where these groups are positioned in relation to each other on the molecule, and the overall molecular shape.

InChI:InChI=1/C14H12O2S/c15-14(16)10-11-6-4-5-9-13(11)17-12-7-2-1-3-8-12/h1-9H,10H2,(H,15,16)

Upstream product

• 108-98-5 thiophenol 
• 66370-75-0 methyl (2-iodophenyl)acetate 
• 37527-78-9 (2-phenylsulfanyl-phenyl)-acetic acid methyl ester 
• 945-51-7 1,1'-sulfinylbisbenzene 
• 18698-96-9 o-iodophenylacetic acid 
• 1527-12-4 2-(phenylthio)benzoic acid 
• 13963-35-4 2-(phenylthio)toluene 
• 1527-14-6 phenyl 2-hydroxymethylphenyl sulfide 
• 88-67-5 2-Iodobenzoic acid 
• 1527-16-8 2-phenylthiophenylacetonitrile 
• 1527-13-5 2-Phenylthiobenzoesaeureethylester 
• 37660-43-8 2-(phenylthio)benzyl bromide 
• 1527-15-7 2-(phenylthio)benzyl chloride 

Downstream Products

• 1898-85-7 dibenzo[b,f]thiepin-10(11H)-one 

Relevant articles and documents

Redox-Neutral α-Arylation of Alkyl Nitriles with Aryl Sulfoxides: A Rapid Electrophilic Rearrangement

A facile α-arylation of nitriles has been developed by simply introducing Tf2O and DABCO to the mixture of nitriles and aryl sulfoxides. The transformation consists of two sequential steps: (i) Tf2O-initiated electrophilic assembly a

Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

Malaria remains a significant infectious disease with even artemisinin-based therapies now facing resistance in the field. Development of new therapies is urgently needed, either by finding new compounds with unique modes of action, or by reversing resistance towards known drugs with 'chemosensitizers' or 'chemoreversal' agents (CRA). Concerning the latter, we have focused on the resistance mechanisms developed against chloroquine (CQ). We have synthesized a series of compounds related to previously identified CRAs, and found promising novel compounds. These compounds show encouraging results in a coumarin labeled chloroquine uptake assay, exhibiting a dose response in resensitising parasites to the antimalarial effects of chloroquine. Selected compounds show consistent potency across a panel of chloroquine and artemisinin sensitive and resistant parasites, and a wide therapeutic window. This data supports further study of CRAs in the treatment of malaria and, ultimately, their use in chloroquine-based combination therapies.

SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.